Research Article| Volume 56, ISSUE 6, P598-603, June 2003

Prospective study of fibrinolytic markers and venous thromboembolism


      Prior research has conflicted on whether increased levels of plasma fibrinolytic factors may identify patients at risk of venous thromboembolism (VTE). We therefore performed a nested case–control study of VTE within two prospective population-based studies. In 308 participants who developed VTE and 640 controls, we measured PAI-1 antigen, tPA/PAI-1 complex, plasmin-α2-antiplasmin (PAP), and the PAI-1 −675 4G/5G promoter polymorphism on pre-event blood samples. There was no overall association between any of these fibrinolytic variables and VTE, after adjustment for age or for multiple VTE risk factors. There was weak evidence for an interaction of PAP with elevated factor VIIIc and elevated D-dimer in augmenting VTE risk. We conclude that, for the most part, these fibrinolytic markers do not identify healthy subjects at risk for VTE.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Prins M.H
        • Hirsh J
        A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism.
        Arch Intern Med. 1991; 151: 1721-1731
        • Ridker P.M
        • Vaughan D.E
        • Stampfer M.J
        • Manson J.E
        • Shen C
        • Newcomer L.M
        • Goldhaber S.Z
        • Hennekens C.H
        Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
        Circulation. 1992; 85: 1822-1827
        • Lowe G.D.O
        • Haverkate F
        • Thompson S.G
        • Turner R.M
        • Bertina R.M
        • Turpie A.G.G
        • Mannucci P.M
        • on behalf of the ECAT DVT Study Group
        Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: The ECAT DVT Study.
        Thromb Haemost. 1999; 81: 879-886
        • Crowther M.A
        • Roberts J
        • Roberts R
        • Johnston M
        • Stevens P
        • Skingley P
        • Patrassi G.M
        • Sartori M.T
        • Hirsh J
        • Prandoni P
        • Weitz J.I
        • Gent M
        • Ginsberg J.S
        Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
        Thromb Haemost. 2001; 85: 390-394
        • Schulman S
        • Wiman B
        The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group.
        Thromb Haemost. 1996; 75: 607-611
        • Ridker P.M
        • Hennekens C.H
        • Lindpaintner K
        • Stampfer M.J
        • Miletich J.P
        Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.
        Circulation. 1997; 95: 59-62
        • Stegnar M
        • Uhrin P
        • Peternel P
        • Mavri A
        • Salobir-Pajnic B
        • Stare J
        • Binder B.R
        The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
        Thromb Haemost. 1998; 79: 975-979
        • Sartori M.T
        • Wiman B
        • Vettore S
        • Dazzi F
        • Girolami A
        • Patrassi G.M
        4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
        Thromb Haemost. 1998; 80: 956-960
        • Grubic N
        • Stegnar M
        • Peternel P
        • Kaider A
        • Binder B.R
        A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.
        Thromb Res. 1996; 84: 431-443
        • Zoller B
        • Garcia de Frutos P
        • Dahlback B
        A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
        Thromb Haemost. 1998; 79: 802-807
        • Akar N
        • Yilmaz E
        • Akar E
        • Avcu F
        • Yalcin A
        • Cin S
        Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A.
        Thromb Res. 2000; 97: 227-230
        • Segui R
        • Estelles A
        • Mira Y
        • Espana F
        • Villa P
        • Falco C
        • Vaya A
        • Grancha S
        • Ferrando F
        • Aznar J
        PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
        Br J Haematol. 2000; 111: 122-128
        • Tassies D
        • Espinosa G
        • Munoz-Rodriguez F.J
        • Freire C
        • Cervera R
        • Monteagudo J
        • Maragall S
        • Escolar G
        • Ingelmo M
        • Ordinas A
        • Font J
        • Reverter J.C
        The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome.
        Arthritis Rheum. 2000; 43: 2349-2358
        • Hooper W.C
        • Lally C
        • Austin H
        • Renshaw M
        • Dilley A
        • Wenger N.K
        • Phillips D.J
        • Whitsett C
        • Rawlins P
        • Evatt B.L
        The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism.
        Thromb Res. 2000; 99: 223-230
        • Morange P.E
        • Henry M
        • Tregouet D
        • Granel B
        • Aillaud M.F
        • Alessi M.C
        • Juhan-Vague I
        The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers.
        Arterioscler Thromb Vasc Biol. 2000; 20: 1387-1391
        • Tsai A.W
        • Cushman M
        • Rosamond W.D
        • Heckbert S.R
        • Polak J.F
        • Folsom A.R
        Cardiovascular risk factors and venous thromboembolism incidence: The Longitudinal Investigation of Thromboembolism Etiology (LITE) Study.
        Arch Intern Med. 2002; 162: 1182-1189
        • Tsai A.W
        • Cushman M
        • Rosamond W.D
        • Heckbert S.R
        • Tracy R
        • Aleksic N
        • Folsom A.R
        Coagulation factors, inflammation markers and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology (LITE) Study.
        Am J Med. 2002; 113: 636-642
        • Cushman M
        • Folsom A.R
        • Aleksic N
        • Rosamond W
        • Tracy R.P
        • Heckbert S
        Fibrin fragment D-dimer and the risk of future venous thrombosis.
        Blood. 2003; 101: 1243-1248
        • Folsom A.R
        • Cushman M
        • Tsai M.Y
        • Aleksic N
        • Heckbert S.R
        • Boland L.L
        • Tsai A.W
        • Yanez N.D
        • Rosamond W.D
        A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.
        Blood. 2002; 99: 2720-2725
        • Folsom A.R
        • Cushman M
        • Tsai M.Y
        • Heckbert S.R
        • Aleksic N
        Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration and incidence of venous thromboembolism.
        Am J Hematol. 2002; 71: 285-290
        • de Ronde H
        • Bertina R
        Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria.
        Thromb Haemost. 1994; 72: 880-886
        • Bertina R.M
        • Koeleman B.P
        • Koster T
        • Rosendaal F.R
        • Dirven R.J
        • de Ronde H
        • van der Velden P.A
        • Reitsma P.H
        Mutation in blood coagulation factor V associated with resistance to activated protein C.
        Nature. 1994; 369: 64-67
        • Declerck P.J
        • Mombaerts P
        • Holvoet P
        • De Mol M
        • Collen D
        Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
        Thromb Haemost. 1987; 58: 1024-1029
        • Cushman M
        • Cornell E.S
        • Howard P.R
        • Bovill E.G
        • Tracy R.P
        Laboratory methods and quality assurance in the Cardiovascular Health Study.
        Clin Chem. 1995; 41: 264-270
        • Conlan M.G
        • Folsom A.R
        • Finch A
        • Davis C.E
        • Sorlie P
        • Marcucci G
        • Wu K.K
        Associations of Factor VIII and von Willebrand Factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study.
        Thromb Haemost. 1993; 70: 380-385
        • Holvoet P
        • deBoer A
        • Verstreken M
        • Collen D
        An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha-2-antiplasmin complex in human plasma—application to the detection of in vivo activation of the fibrinolytic system.
        Thromb Haemost. 1986; 56: 124-127
        • Declerck P.J
        • Alessi M.C
        • Verstreken M
        • Kruithof E.K
        • Juhan-Vague I
        • Collen D
        Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.
        Blood. 1988; 71: 220-225
        • Declerck P.J
        • Collen D
        Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays.
        Thromb Res Suppl. 1990; 10: 3-9
        • Dawson S
        • Hamsten A
        • Wiman B
        • Henney A
        • Humphries S
        Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor-1 activity.
        Arterioscler Thromb. 1991; 11: 183-190
        • Sakkinen P.A
        • Cushman M
        • Psaty B.M
        • Rodriguez B
        • Boineau R
        • Kuller L.H
        • Tracy R.P
        Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
        Arterioscler Thromb Vasc Biol. 1999; 19: 499-504
        • Rothman K.J
        • Greenland S
        Modern epidemiology.
        2nd ed. Lippincott-Raven Publishers, Philadelphia, PA1998 (p. 335)
        • Lewis M.R
        • Callas P.W
        • Jenny N.S
        • Tracy R.P
        Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples.
        Thromb Haemost. 2001; 86: 1495-1500